Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis

BACKGROUND: Multiple sclerosis is an inflammatory demyelination process in the central nervous system (CNS) causing neurological disability and poor quality of life. Currently, Thai Food and Drug Administration (FDA)-approved disease-modifying therapy is costly, and most patients with multiple scler...

Descripción completa

Detalles Bibliográficos
Autores principales: Aungsumart, Saharat, Turongkaravee, Saowalak, Youngkong, Sitaporn, Apiwattanakul, Metha, Thakkinstian, Ammarin, Chaikledkaew, Usa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571281/
https://www.ncbi.nlm.nih.gov/pubmed/37833729
http://dx.doi.org/10.1186/s12913-023-10099-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571281/
https://www.ncbi.nlm.nih.gov/pubmed/37833729
http://dx.doi.org/10.1186/s12913-023-10099-1

Ejemplares similares